Structured JSON API for this factor page: https://sharemaestro.com/factors/api/tickers/d62f7cbd-c740-47d1-be62-18a10e7429ab/

GUFICBIO

Gufic Biosciences Limited
Chart
₹369.95
Latest Week 2026-06-05
HealthcareDrug Manufacturers - Specialty & GenericLARGE
Snapshot 2026-06-07 · 0.0w · Fresh
0.17
OS Score
10.0%
Value
52.0%
Quality
64.0%
Momentum
5/9
F-Score
0.228
QV
StrategiesValueQualityMomentumCompositeInteractionsFactor AnalysisTrendsFundamentals
Strategy Eligibility
0 of 23 passing
★
OS Composite
✗
↗
Trending Value
✗
◆
Quality × Value
✗
🏛
Cornerstone Value
✗
🌿
Cornerstone Growth
✗
💎
Deep Value
✗
◇
VC2 Cheapest
✗
📐
EBITDA/EV
✗
◐
Veiled Value
✗
▣
Piotroski Bargains
✗
🔬
Quality Compounders
✗
📈
Consistent Earners
✗
🌱
GARP
✗
🔄
Shareholder Yield
✗
💰
High Yield
✗
🚀
Momentum Leaders
✗
◉
Market Leaders
✗
◎
Tiny Titans
✗
🔍
Small Cap Value
✗
🛡
Low Volatility
✗
🏷
Sector Cheapest
✗
🧠
Capital Allocators
✗
⚡
Risk-Adj Momentum
✗
V
Value Analysis
Cheapness relative to fundamentals
10.0%ile
P/E
57.8×
P/S
3.9×
P/B
5.6×
E/P
0.0173
FCF Yield
0.003
EBITDA/EV
0.038
SH Yield
0.000
Relative Strength Across Value Dimensions
Multiples & Yields — Decomposition
VC1 (5-Factor)
91.00000000
/100 — 1=cheapest
VC2 (Trending Value)
93.00000000
/100
VC3 (Buyback)
93.00000000
/100
P/E of 57.8x is premium-priced — the market is paying up for expected growth. VC2 score of 93.00000000/100 — expensive across all six composite measures.
Q
Quality Analysis
Profitability, efficiency, balance sheet & earnings quality
52.0%ile
ROE
0.097
ROA
0.048
Net Margin
0.068
Op Margin
0.128
GPA
0.389
Current
1.55
F-Score
5/9
Quality Radar — Relative Strength
Profitability & Leverage Breakdown
Rev Growth
0.152
Earn Growth
-0.078
Stability
0.368
lower=better
Accruals
0.014
lower=better
5yr Consist
No
M
Momentum & Risk
Price trend, volatility regime, risk-adjusted returns
64.0%ile
6M Return
4.1%
12M Return
0.5%
12-1 Mom
-17.8%
Risk-Adj
-0.55
Vol 252d
32.3%
Vol 60d
74.3%
↑ Expanding
Max DD 12M
-27.9%
Return Comparison — 6M / 12M / 12-1
Volatility Regime — 60d vs 252d
12-1 momentum of -18% signals a downtrend — price is moving against you. Near-term vol (74%) is expanding vs long-term (32%) — risk is increasing.
OS
Composite & Factor Heatmap
All factors at a glance
0.17
Pillar Balance — Value / Quality / Momentum
Factor Heatmap — green=strong, red=weak
▦
Sector Context
Healthcare · 160 peers
Sector Value %ile
21.7%
Sector Quality %ile
32.3%
P/E z-score
-0.10
P/B z-score
0.01
Sector Avg OS
43.9%
Ticker vs Sector Averages
Relative Valuation Z-Score
Top Sector Peers (By OS)
SymbolNameOSValueQualityMomentum
NATCOPHARM NATCO Pharma Limited 98.0% 88.0% 87.0% 81.0%
UNIVPHOTO Universus Photo Imagings Limited 97.0% 86.0% 74.0% 94.0%
LINCOLN Lincoln Pharmaceuticals Limited 97.0% 88.0% 80.0% 81.0%
STAR Strides Pharma Science Limited 96.0% 73.0% 91.0% 91.0%
VENUSREM Venus Remedies Limited 96.0% 68.0% 94.0% 99.0%
HALEOSLABS Haleos Labs Limited 95.0% 82.0% 77.0% 81.0%
AUROPHARMA Aurobindo Pharma Limited 94.0% 71.0% 84.0% 87.0%
SPARC Sun Pharma Advanced Research Company Limited 93.0% 72.0% 86.0% 83.0%
Factor Interactions
Volatility Expanding
60-day vol (74%) significantly exceeds 252-day (32%). Near-term risk is elevated.
⚖
Factor Analysis
Comprehensive factor intelligence — strengths, weaknesses & cross-factor profile
Value
F
23.7% avg (7 factors)
Quality
C
45.1% avg (7 factors)
Momentum
F
24.3% avg (4 factors)
Risk
B
62.9% avg (1 factors)
Momentum is weak, suggesting the market isn't yet buying this thesis. Patience required.
▲ Top Strengths — highest scoring factors
▼ Key Weaknesses — lowest scoring factors
Factor Persistence1 snapshots
FactorCurrentStreakTrendSpark
OS Composite0.170—1—
Value %ile0.100—1—
Quality %ile0.520—0—
Momentum %ile0.640—0—
F-Score5.000—0—
Confidence0.939—1—
Volatility0.323—0—
Value FactorsCheapness relative to fundamentals — lower multiples = cheaper
P/E Ratio
57.77
Earnings Yield (E/P)
0.0173
Price / Sales
3.93
Price / Book
5.58
Price / Cash Flow
82.50
FCF Yield
0.3%
EBITDA / EV
3.8%
Sales Yield (1/P·S)
0.2329
Shareholder Yield
Div + net buyback / mktcap
-0.0%
Quality FactorsProfitability, efficiency, and balance sheet strength
Return on Equity
9.7%
Return on Assets
4.8%
Net Margin
6.8%
Operating Margin
12.8%
Gross Profit / Assets
Novy-Marx GPA
38.9%
Current Ratio
1.55
Accruals Ratio
(NI-OCF)/Assets — lower=better
0.014
MomentumPrice trend strength over different horizons
6M Return
4.1%
12M Return
0.5%
12-1 Momentum
Jegadeesh-Titman (skip recent month)
-17.8%
Risk-Adjusted Momentum
Mom 12-1 ÷ Vol
-0.55
Growth & StabilityEarnings trajectory, consistency, and capital allocation
Revenue Growth (YoY)
15.2%
Earnings Growth (YoY)
-7.8%
Earnings Stability (CV)
Lower = more stable
0.368
5yr Consistent
EPS up every year for 5 years
No
Piotroski F-Score
5
Dividend Yield
0.0%
Buyback Yield
-0.0%
O'Shaughnessy CompositesValue Composites (WWOWS 4th Ed) — 1=cheapest, 100=most expensive
VC1 (5-factor)
P/E+P/S+P/B+P/CF+EBITDA/EV
91
VC2 (6-factor)
VC1 + Shareholder Yield — used for Trending Value
93
VC3 (6-factor)
VC1 + Buyback Yield — no dividend preference
93
Capital Allocation & AlphaAlpha within factors — quality of management decisions
Veiled Value
Expensive by P/B, cheap by everything else
No
Market Leader
Above-avg mcap+revenue, non-utility
No
All Stocks Universe
Market cap > $200M
Yes
Tiny Titan
Micro-cap, low P/S, positive momentum
No
Quarterly Fundamentals
Revenue
Net Income
FCF
Net Margin
Show all
Op Income
OCF
CapEx
Equity
Annual Fundamentals
Revenue
Net Income
FCF
Net Margin
Show all
Op Income
OCF
CapEx
Equity